Novavax’s RSV vaccine fails second Phase III trial, further shrinking its pathways to success, says GlobalData
Following the news on 28 February 2019 that Novavax’s respiratory syncytial virus (RSV) disease vaccine for infants – ResVax – did not meet its primary Phase III en...



